跳至主要内容
临床试验/EUCTR2013-005087-25-ES
EUCTR2013-005087-25-ES进行中(未招募)不适用

Gemcitabine plus nab-paclitaxel versus folfirinox as neoadjuvant treatment in patients with potentially resectable pancreatic carcinoma. NeoPAN Study - NeoPA

FUNDACION HOSPITAL DE MADRID0 个研究点开始时间: 2014年4月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1- Patients with cytological or anathomopathological diagnosis of pancreatic carcinoma
  • 2- The pancreatic tumor is resectable or borderline
  • 3- Older than 18 years
  • 4- ECOG performance status 0-1
  • 5- Adequate hematologic function:
  • a. Neutrophils > 1.500
  • b. Hemoglobin > 9
  • c. Platelets > 100.000
  • 6- Adequate liver and kidney function:
  • a. Bilirubin <= 1,5 ULN
  • b. AST <= 3 ULN
  • c. ALT ? 3 ULN
  • d. Creatinine clearance >= 40ml/min
  • 7- Signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 14

排除标准

  • 1.- Patients unable to complete the study procedures for geographical, psychiatric or social reasons.
  • 2.- Patients with some physical or psychical condition which contraindicates the study treatment
  • 3.- Patients with active infection or another significant or autoimmune disease.
  • 4.- ECOG performance status >= 2.
  • 5.- Chronic hepatic disease (cirrhosis, chronic hepatitis)
  • 6.- Another solid or hematologic concurrent tumor or previous tumors for the last 5 years. (except for basal cell carcinoma and skin epidermoid no relapsed tumors)
  • 7.- Pregnancy or breastfeeding period. Women of child-bearing potential and men have to use contraceptive methods or be surgically sterilized.
  • 8.- Patients who are taking oral anticoagulants and it cannot be replaced for subcutaneous low molecular weight heparin.
  • 9.- Distant pancreatic cancer metastasis.
  • 10.- Patients who have been previously treated for pancreatic carcinoma with radiotherapy, chemotherapy or surgical treatment different from biliary derivation or biopsy.
  • 11.- Impossibility or contraindication to complete any study procedure (Eco-endoscopy, NMR, MisoPET)
  • 12.- Prior history of neuropathy or polyneuropathy

研究者

发起方
FUNDACION HOSPITAL DE MADRID

相似试验